In a recent article by Rothman et al., secondary analysis of the CANTOS trial suggested that while IL-1β inhibition with canakinumab reduced cardiovascular event rates, this benefit may not be related to incident hypertension and raises the question of the importance of inflammation in hypertension and development of cardiovascular disease [122•]. This evidence concerns the gene IL1B and hypertensive disorder.